Is lipoprotein(a) a risk factor for ischemic stroke and venous thromboembolism?

被引：10
作者：
Nave A.H. [1 ,2 ,3 ,4 ]
von Eckardstein A. [5 ]
机构：
[1] Klinik und Hochschulambulanz für Neurologie, Charité-Universitätsmedizin Berlin, Charitéplatz 1, Berlin
[2] Center for Stroke Research Berlin (CSB), Charité-Universitätsmedizin Berlin, Berlin
[3] Berlin Institute of Health (BIH), Berlin
[4] German Center for Cardiovascular Research (DZHK), partner site Berlin, Berlin
[5] Institute of Clinical Chemistry, University and University Hospital of Zurich, Raemistraße 100, Zurich
来源：
Clinical Research in Cardiology Supplements | 2019年 / 14卷 / Suppl 1期
关键词：
Atherosclerosis; Ischemic stroke; Lipoprotein a; Low-density lipoproteins; Venous thrombosis;
D O I：
10.1007/s11789-019-00101-8
中图分类号：
学科分类号：
摘要：
The structural similarity with plasminogen as well as thrombogenic and atherogenic in vitro functions raise the question if lipoprotein(a) (Lp(a)) is a risk factor for venous thromboembolism (VTE) and ischemic stroke. Numerous case–control and prospective studies using different cut-off values to define high Lp(a) generated conflicting evidence for both VTE and ischemic stroke. Several meta-analyses demonstrated independent associations of elevated Lp(a) with a history of VTE or ischemic stroke. However, the evidence of prospective studies for associations of Lp(a) with incident stroke or recurrent VTE remains inconclusive. For ischemic stroke, data suggest that Lp(a) increases the risk of large-artery atherosclerosis stroke, but not cardioembolic or lacunar stroke. Lp(a) may increase the risk of VTE in the presence of additional thrombophilic risk factors. Larger cohort studies are needed to elaborate the importance of higher Lp(a) cut-offs and interactions with other risk factors and subgroups of stroke or VTE. The value of Lp(a) to estimate residual vascular risk after the first thromboembolic event remains to be adequately explored. © 2019, The Author(s).
引用
收藏
页码：28 / 32
页数：4
相关论文
共 33 条
  • [1] Gencer B., Kronenberg F., Stroes E.S., Mach F., Lipoprotein(a): the revenant, Eur Heart J, 38, pp. 1553-1560, (2017)
  • [2] Schmidt K., Noureen A., Kronenberg F., Utermann G., Structure, function, and genetics of lipoprotein (a), J Lipid Res, 57, pp. 1339-1359, (2016)
  • [3] Boffa M.B., Koschinsky M.L., Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?, J Lipid Res, 57, pp. 745-757, (2016)
  • [4] Sacco R.L., Kasner S.E., Broderick J.P., Et al., An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American heart association/American stroke association, Stroke, 44, pp. 2064-2089, (2013)
  • [5] Feigin V.L., Norrving B., Mensah G.A., Global burden of stroke, Circ Res, 120, pp. 439-448, (2017)
  • [6] Amarenco P., Lavallee P.C., Monteiro Tavares L., Et al., Five-year risk of stroke after TIA or minor Ischemic stroke, N Engl J Med, 378, pp. 2182-2190, (2018)
  • [7] Adams H.P., Bendixen B.H., Jaap Kappelle L., Et al., Classification of subtype of acute Ischemic stroke definitions for use in a multicenter clinical trial, Stroke, 24, pp. 35-41, (1993)
  • [8] Li L., Yiin G.S., Geraghty O.C., Et al., Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: A population-based study, Lancet Neurol, 14, pp. 903-913, (2015)
  • [9] Koltringer P., Jurgens G., A dominant role of lipoprotein(a) in the investigation and evaluation of parameters indicating the development of cervical atherosclerosis, Atherosclerosis, 58, pp. 187-198, (1985)
  • [10] Zenker G., Koltringer P., Bone G., Et al., Lipoprotein(a) as a strong indicator for cerebrovascular disease, Stroke, 17, pp. 942-945, (1986)
1234